AA
WVE icon

AlphaCentric Advisors’s Wave Life Sciences WVE Stock Holding History

AlphaCentric Advisors’s Portfolio WVE Stock Details WVE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$212K Buy
29,175
+1,585
+6% +$20.6K 0.21% 140
2025
Q4 		$469K Buy
+27,590
New +$280K 0.47% 67

Other funds holding WVE

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
GP
GSK plc London $599M AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

AlphaCentric Advisors's WVE Position: Q1 2026 in Review

AlphaCentric Advisors increased its Wave Life Sciences (WVE) stake by 5.7% in Q1 2026, buying an estimated $20.6K and bringing the position to 29,175 shares worth $212K. The position accounts for 0.21% of the portfolio, ranked #140.

AlphaCentric Advisors first reported a position in WVE in Q4 2025 and has held it in 2 quarters since. The position peaked at $469K in Q4 2025. 230 funds tracked by Wall St. Rank hold WVE as of Q1 2026.

  • AlphaCentric Advisors held 29,175 shares of Wave Life Sciences worth $212K as of Q1 2026.
  • AlphaCentric Advisors bought 1,585 Wave Life Sciences shares in Q1 2026, an estimated $20.6K.
  • Wave Life Sciences made up 0.21% of AlphaCentric Advisors's portfolio in Q1 2026, its #140 holding.
  • AlphaCentric Advisors first reported a position in Wave Life Sciences in Q4 2025 and has held it in 2 quarters since.
  • AlphaCentric Advisors's Wave Life Sciences position peaked at $469K in Q4 2025.
  • 230 funds tracked by Wall St. Rank held Wave Life Sciences as of Q1 2026.

Based on AlphaCentric Advisors's 13F filing for Q1 2026, filed 7 May 2026.